Supernus Pharmaceuticals (SUPN) Cash from Operations (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Cash from Operations data on file, last reported at 66524000.0 in Q1 2026.

• Cash from Operations for Q1 2026 came in at 66524000.0, up 117.41% year-over-year; the trailing twelve-month figure through Mar 2026 was 83256000.0 (down 49.28% YoY), and the FY2025 annual result was 47331000.0, down 72.47% from the prior year.
• Cash from Operations rose to 66524000.0 in Q1 2026 per SUPN's latest filing, from 19861000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 71119000.0 in Q2 2022 and troughed at 61664000.0 in Q3 2025.
• A 5-year average of 30218647.06 and a median of 35875000.0 in 2023 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2023 and 2025: Cash from Operations surged 1041.93% in 2023, then sank 215.22% in 2025.
• A 5-year view of Cash from Operations shows it stood at 27564000.0 in 2022, then jumped by 63.1% to 44958000.0 in 2023, then slipped by 1.23% to 44406000.0 in 2024, then plunged by 55.27% to 19861000.0 in 2025, then jumped by 234.95% to 66524000.0 in 2026.
• Business Quant data shows SUPN's Cash from Operations at 66524000.0 in Q1 2026, 19861000.0 in Q4 2025, and 61664000.0 in Q3 2025.